In mouse models of breast cancer, interruption of CCL2/CCR2 signaling leads to acceleration of tumor metastasis as a result of massive release of monocytes [312], indicating that more potential compensatory factors should be considered to achieve optimal and durable effects when exploring TAM-targeted strategies. The gene discussed is CCL2; the disease is breast cancer.